On June 10, PIPC submitted a comment letter on the Institute for Clinical and Economic Review’s (ICER) assessment of anemia in myelodysplastic syndrome (MDS).
The letter highlights several flaws in ICER’s model, including its assumption of patient responsiveness to treatment based on health dependance state and exclusion of non-drug costs for ongoing treatment of MDS. PIPC is also concerned with ICER's continued use of the discriminatory QALY and similar measure eyLYG in its assessment.
“The eyLYG is a simplistic fix attempting to address criticism that the QALY devalues life years lived with a disability, yet it fails to account for oversimplified measures of quality-of-life gains in expected life years and it does not account for any health improvements in extended life years,” wrote PIPC Chair Tony Coelho. “With the evLYG and the QALY, ICER promotes two compromised and flawed measures of health gain. Deciding which to choose is confusing and inconsistent.”
“The eyLYG is a simplistic fix attempting to address criticism that the QALY devalues life years lived with a disability, yet it fails to account for oversimplified measures of quality-of-life gains in expected life years and it does not account for any health improvements in extended life years,” wrote PIPC Chair Tony Coelho. “With the evLYG and the QALY, ICER promotes two compromised and flawed measures of health gain. Deciding which to choose is confusing and inconsistent.”
| icer_anemia_in_myelodysplastic_syndrome_final.pdf |
